Nutex Health, Inc. NUTX
We take great care to ensure that the data presented and summarized in this overview for Nutex Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NUTX
Top Purchases
Top Sells
About NUTX
Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.
Insider Transactions at NUTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 08
2025
|
Jon Christian Bates Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+16.98%
|
$81,000
$81.81 P/Share
|
|
Apr 04
2025
|
Kelvin Spears Director |
SELL
Payment of exercise price or tax liability
|
Direct |
34
-0.11%
|
$2,448
$72.1 P/Share
|
|
Apr 04
2025
|
Joshua De Tillio Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
452
-6.52%
|
$32,544
$72.1 P/Share
|
|
Apr 04
2025
|
Pamela W. Montgomery Chief Legal Officer-Healthcare |
SELL
Payment of exercise price or tax liability
|
Direct |
290
-11.04%
|
$20,880
$72.1 P/Share
|
|
Apr 04
2025
|
Michael L. Chang Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Indirect |
266
-0.33%
|
$19,152
$72.1 P/Share
|
|
Apr 04
2025
|
Thomas T. Vo Chief Executive Officer |
BUY
Payment of exercise price or tax liability
|
Indirect |
895
+0.05%
|
$64,440
$72.1 P/Share
|
|
Apr 04
2025
|
Warren Hosseinion President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,072
-23.85%
|
$77,184
$72.1 P/Share
|
|
Apr 04
2025
|
Elisa V Luqman Chief Legal Officer - SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
266
-19.91%
|
$19,152
$72.1 P/Share
|
|
Mar 01
2025
|
Jon Christian Bates Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,611
+16.14%
|
-
|
|
Mar 01
2025
|
Kelvin Spears Director |
BUY
Exercise of conversion of derivative security
|
Direct |
143
+0.44%
|
-
|
|
Mar 01
2025
|
Joshua De Tillio Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,125
+23.46%
|
-
|
|
Mar 01
2025
|
Pamela W. Montgomery Chief Legal Officer-Healthcare |
BUY
Exercise of conversion of derivative security
|
Direct |
1,361
+32.28%
|
-
|
|
Mar 01
2025
|
Michael L. Chang Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,250
+1.51%
|
-
|
|
Mar 01
2025
|
Thomas T. Vo Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
5,000
+0.27%
|
-
|
|
Mar 01
2025
|
Warren Hosseinion President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,776
+45.66%
|
-
|
|
Mar 01
2025
|
Elisa V Luqman Chief Legal Officer - SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+48.34%
|
-
|
|
Jan 08
2025
|
Thomas T. Vo Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
5,000
+0.27%
|
-
|
|
Aug 22
2024
|
Jon Christian Bates Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,350
+37.22%
|
$28,350
$21.46 P/Share
|
|
Aug 20
2024
|
Joshua De Tillio Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
575
+10.68%
|
$9,775
$17.4 P/Share
|
|
Aug 19
2024
|
Joshua De Tillio Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
1,300
+23.5%
|
$22,100
$17.85 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 16.5K shares |
|---|---|
| Grant, award, or other acquisition | 22.7K shares |
| Payment of exercise price or tax liability | 895 shares |
| Bona fide gift | 5K shares |
| Open market or private purchase | 96.7K shares |
| Payment of exercise price or tax liability | 2.38K shares |
|---|